Phase 2 study of ONT-380 in combination with Kadcyla in patients with CNS metastases

Trial Profile

Phase 2 study of ONT-380 in combination with Kadcyla in patients with CNS metastases

Planning
Phase of Trial: Phase II

Latest Information Update: 11 Dec 2015

At a glance

  • Drugs Tucatinib (Primary) ; Trastuzumab emtansine
  • Indications Brain metastases
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Dec 2015 New trial record
    • 08 Dec 2015 According to Oncothyreon media release, company is planning to discuss about the designs of this trial, together with the overall registration strategy, with the regulatory authorities that includes the US FDA, in the first part of 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top